共 50 条
- [41] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy studyJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Fan, BinAbou-Alfa, Ghassan K.Zhu, Andrew X.Pandya, Shuchi SumantJia, HongxiaYin, FengJiang, LiewenGliser, CameliaYang, Hua
- [42] Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of GliomaACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (02): : 101 - 107Konteatis, ZenonArtin, ErinNicolay, BrandonStraley, KimberlyPadyana, Anil K.Jin, LeiChen, YueNarayaraswamy, RohiniTong, ShuilongWang, FengZhou, DingCui, DaweiCai, ZhenweiLuo, ZhiyongFang, ChengTang, HuachunLv, XiaobingNagaraja, RajYang, HuaSu, Shin-San M.Sui, ZhihuaDang, LennyYen, KatharinePopovici-Muller, JanetaCodega, PaoloCampos, CarlMellinghoff, Ingo K.Biller, Scott A.
- [43] A genome-wide CRISPR screen identifies ARID1A as a potential resistance marker of IDH1 inhibitor in IDH1-mutant cholangiocarcinoma cellCANCER RESEARCH, 2024, 84 (06)Kondo, TomohiroKikuchi, OsamuWang, YafengNakai, YukieIda, TomomiCao, YangVu, Trang H.Kondo, YukiSunami, TomohikoYamamoto, YoshihiroSaito, TomokiKataoka, ShigekiYamada, AtsushiKanai, MasashiOhashi, ShinyaMuto, Manabu
- [44] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATIONNEURO-ONCOLOGY, 2018, 20 : 18 - 18Mellinghoff, IngoPenas-Prado, MartaPeters, KatherineCloughesy, TimothyBurris, HowardMaher, ElizabethJanku, FilipCote, GregoryDe La Fuente, MacarenaClarke, JenniferSteelman, LoriLe, KhaXu, HuanshengSonderfan, AlisonHummel, DianaSchoenfeld, StevenYen, KatharinePandya, ShuchiWen, Patrick
- [45] Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S340 - S340DiNardo, Courtney D.Foran, James M.Watts, Justin M.Stein, Eytan M.De Botton, StephaneFathi, Amir T.Prince, Gabrielle T.Stein, Anthony S.Stone, Richard M.Patel, Prapti A.Tallman, Martin S.Choe, SungWang, HongfangZhang, VickieDai, DavidFan, BinYen, Katherine E.Kapsalis, Stephanie K.Hickman, DeniceAgresta, Samuel V.Liu, HuaWu, BinAttar, Eyal C.Kantarjian, Hagop M.
- [46] Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcomaJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Tap, William D.Cote, Gregory MichaelBurris, Howard A.Gore, LiaBeeram, MuralidharConley, Anthony PaulGianolio, Diego A.Qu, ZheGliser, CameliaPandya, Shuchi SumantTrent, Jonathan C.
- [47] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Pauff, James MichaelPapadopoulos, Kyriakos P.Janku, FilipTurk, Anita AhmedGoyal, LipikaShroff, Rachna T.Shimizu, ToshioIkeda, MasafumiAzad, Nilofer SabaCleary, James M.Peters, Mary Linton BounetheauBorad, Mitesh J.Jaeckle, Kurt A.Kizilbash, Sani HaiderTupper, RebeccaFurin, Carrie E.Hanley, Matthew P.Hill, Elizabeth GoodwinXu XiaojianHarding, James J.
- [48] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid LeukemiaBLOOD, 2022, 140 : 6170 - 6172Atluri, HimachandanaMaiti, AbhishekSasaki, KojiDaver, NavalAlvarado, YesidHossain, Md FerozWang, XuemeiPemmaraju, NaveenTakahashi, KoichiBorthakur, GautamFerrajoli, AlessandraShort, NicholasAbbas, Hussein A.Ravandi, FarhadJabbour, EliasAndreeff, MichaelGarcia-Manero, GuillermoKantarjian, HagopKonopleva, MarinaDiNardo, Courtney D.
- [49] COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVONEURO-ONCOLOGY, 2017, 19 : 79 - 79Nicolay, BrandonNarayanaswamy, RohiniAmatangelo, Michael D.Aguado, EliaNagaraja, RajMurtie, JoshLiu, GuowenIshii, Yuko
- [50] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 UpdateBLOOD, 2023, 142Atluri, HimachandanaMullin, JillianTakahashi, KoichiLoghavi, SanamMaiti, AbhishekSasaki, KojiDaver, NavalValero, Yesid AlvaradoPemmaraju, NaveenBorthakur, GautamHammond, Danielle E.Chien, Kelly S.Ferrajoli, AlessandraShort, Nicholas J.Abbas, Hussein A.Jabbour, EliasAndreeff, MichaelRavandi, FarhadTidwell, Rebecca S. S.Wang, XuemeiKonopleva, Marina Y.Garcia-Manero, GuillermoKantarjian, Hagop M.DiNardo, Courtney D.